Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Saniona AB
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Saniona AB
STO:SANION
Total Current Assets
kr74.2m
CAGR 3-Years
-46%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Total Current Assets
kr21.9B
CAGR 3-Years
3%
CAGR 5-Years
23%
CAGR 10-Years
23%
Zealand Pharma A/S
CSE:ZEAL
Total Current Assets
kr8.7B
CAGR 3-Years
88%
CAGR 5-Years
41%
CAGR 10-Years
38%
Ascendis Pharma A/S
NASDAQ:ASND
Total Current Assets
€973.7m
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
58%
B
Bavarian Nordic A/S
CSE:BAVA
Total Current Assets
kr5.4B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
23%
Bioporto A/S
CSE:BIOPOR
Total Current Assets
kr123.9m
CAGR 3-Years
9%
CAGR 5-Years
13%
CAGR 10-Years
11%
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Saniona AB's Total Current Assets?
Total Current Assets
74.2m SEK

Based on the financial report for Jun 30, 2024, Saniona AB's Total Current Assets amounts to 74.2m SEK.

What is Saniona AB's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-8%

Over the last year, the Total Current Assets growth was -13%. The average annual Total Current Assets growth rates for Saniona AB have been -46% over the past three years , -8% over the past five years .

Back to Top